Innovent details Phase 3 weight loss data from Lilly-partnered GLP-1 in Chinese patients
Innovent Biologics has lifted the curtain on late-stage data from its next-generation “double-G” drug in overweight or obese Chinese patients after the company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.